Abstract:Joan Llach, Sabela Carballal, Leticia Moreira Departmento de Gastroenterología, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain Correspondence: Leticia Moreira Villarroel 170, Barcelona 08036, Spain Tel +34 932275400 Fax +34 932279381 Email lmoreira@clinic.cat Pancreatic cancer (PC) is a highly lethal disease, mostly incurable when detected. Thus, despite advances in PC treatments, only around 7% of patients survive 5-years after diagnosis. This morbid outcome is secondary to multifactorial reasons, such as late-stage diagnosis, rapid progression and minimal response to chemotherapy. Based on these factors, it is of special relevance to identify PC high-risk individuals in order to establish preventive and early detection measures. Although most PC are sporadic, approximately 10% cases have a familial basis. No main causative gene of PC has been identified but several known germline pathogenic mutations are related with an increased risk of this tumor. These inherited cancer syndromes represent 3% of all PC. On the other hand, in 7% of cases of PC, there is a strong family history without a causative germline mutation, a situation known as familial pancreatic cancer (FPC). In recent years, there is increasing evidence supporting the benefit of genetic germline analysis in PC patients, and periodic pancreatic screening in PC high-risk patients (mainly those with a lifetime risk greater than 5%), although there is no general agreement in the group of patients and individuals to study and screen. In the present review, we expose an update in the field of hereditary and FPC, with the aim of describing the current strategies and implications in genetic counseling, surveillance and therapeutic interventions. Keywords: pancreatic cancer, hereditary, familial, mutation, screening, personalized medicine

Hereditary pancreas endocrine neoplasia

Multiple Endocrine Neoplasia Type 1 Related Pancreatic Endocrine Tumors

Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer

Characterization of Single Lesion Nonfunctioning Pancreatic Neuroendocrine Carcinoma Via Computed Tomography

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment

Hereditary pancreatitis of 3 Chinese children: Case report and literature review.

Recent advances in pediatric hereditary neoplastic syndromes

Metastatic Mixed Acinar‐neuroendocrine Carcinoma of the Pancreas Treated by a Multidisciplinary Team: A Case Report and Brief Review of the Literature

Hereditary Pancreatitis of 3 Chinese Children

Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives

Focused Dilemmas in the Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms

Multiple Endocrine Neoplasia Type 1 Simultaneous with Various Types of Enteropancreatic Endocrine Tumors One Case Report: Lessons Learned

[Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 1 Related Pancreatic Endocrine Tumors].

Diagnosis and surgical treatment of multiple endocrine neoplasia type 1

Familial Pancreatic Cancer: Current Perspectives

Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas

Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation

Recent Research Hotspots in Sequencing and the Pancreatic Neuroendocrine Tumor Microenvironment.